Dietrich Stephan

Dietrich Stephan

Directeur/Bestuurslid bij
Epistemix, Inc.

Vermogen: 144 944 $ op 31-10-2026

56 jaar
Consumer Services
Health Technology
Commercial Services

Profiel

Dietrich A. Stephan was the founder of Amnestix, Inc. (founded 2006), serving as Director-Neurogenomics Division; Life Technologies Clinical Services Lab, Inc. (founded 2006), serving as Director & Chief Science Officer from 2007 to 2011; Lifecode, Inc. (founded 2011), serving as President, Chief Executive Officer & Director from 2011 to 2015; and NeuBase Therapeutics, Inc. (founded 2009), serving as Chief Executive Officer & Director from 2022 to 2024.
Dr. Stephan is also the founder of DiaVacs, Inc.,LifeX Holdings LLC..
Dr. Stephan currently serves as Chairman-Neuroscience Microarray Consortium at the National Institutes of Health since 2011; Independent Director at Sharp Therapeutics Corp.
since 2024; Director at FRX Growth Partners LLC; Director at Epistemix, Inc.; Member at National Institute of Health Policy; and Managing Partner at Cyto Ventures since 2018.
Former positions include President & Chief Executive Officer at Neubase Therapeutics, Inc.; Chairman-Human Genetics Department & Professor at the University of Pittsburgh; Chairman-Neurogenomics Department & Professor at Translational Genomics Research Institute; Chairman at Pendulum, Inc.; Chairman at Peptilogics, Inc. from 2016 to 2025; Director at Western Oncolytics Ltd.; Executive Director-Gene Partnership at The Children's Hospital Corp.
and Harvard Medical School; Director at Personalized Medicine Coalition, Sharp Edge Labs, Inc., iGenomX International Genomics LLC, Parabase Genomics, Inc., Ariel Precision Medicine, Inc., CereDx, Inc.; Director at Pendulum Therapeutics, Inc. from 2012 to 2018; Faculty Member at George Washington University, Arizona State University, The Johns Hopkins University, and the University of Arizona; and Chief Science Advisor at FarmaceuticalRX LLC.
Education includes undergraduate studies at Carnegie Mellon University and a doctorate from the University of Pittsburgh Graduate School of Public Health.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
0,77%
21-05-2025 241.574 ( 0,77% ) 144 944 $ 31-10-2026

Actieve functies van Dietrich Stephan

BedrijvenFunctieBegin
Directeur/Bestuurslid -
Directeur/Bestuurslid -
National Institute of Health Policy
Corporate Officer/Principal -
Corporate Officer/Principal 26-07-2011
Cyto Ventures
Corporate Officer/Principal 01-01-2018

Eerdere bekende functies van Dietrich Stephan

BedrijvenFunctieEinde
Voorzitter 01-03-2025
NEUBASE THERAPEUTICS, INC. Algemeen Directeur 16-01-2024
Directeur/Bestuurslid 01-08-2018
Oprichter 01-04-2011
░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░░ ░░░ ░░░░░░░░░░░░░░░░░░░░░ -
Ervaring van Dietrich Stephan in detail bekijken

Opleiding van Dietrich Stephan

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

69

Eerstegraads connecties

33

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit33

Consumer Services

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Health Services

Government

Commercial Services

Health Services

National Institute of Health Policy

Consumer Services

Commercial Services

Commercial Services

Technology Services

Consumer Services

Health Technology

Commercial Services

Health Services

Health Services

Health Technology

Process Industries

Health Technology

Process Industries

Health Technology

LifeX Holdings LLC

Cyto Ventures

Commercial Services

Pendulum, Inc.

Technology Services

  1. Beurs
  2. Insiders
  3. Dietrich Stephan